Table 4. Univariate and multivariate... | American Society of Hematology

Table 4.

Univariate and multivariate analysis of prognostic factors for OS

Variable	Modality	Reference	Univariate analysis			Multivariate analysis
Variable	Modality	Reference	HR	95% CI	P	HR	95% CI	P
Age		Continuous variable	1.05	1.04-1.06	<.001	1.02	1.01-1.03	<.001
ECOG (0-1)	Yes	No	0.23	0.17-0.30	<.001	0.44	0.29-0.66	<.001
Sex	Female	Male	0.86	0.64-1.16	.326
Localization	Disseminated with or without cutaneous localization	Cutaneous isolated	1.57	1.17-2.11	.003	2.31	1.65-3.23	<.001
	Disseminated with cutaneous localization		2.09	1.30-3.35	.002	5.37	3.15-9.	<.001
	Extranodal disease		1.47	0.87-2.51	.154	4.68	2.61-8.40	<.001
Abnormal karyotype	Yes	No	0.78	0.47-1.32	.360
	CK		1.02	0.59-1.77	.938
	MK		0.71	0.33-1.50	.362
Type of treatment	AL-type treatment	NHL-type treatment	0.71	0.51-0.99	.047	0.88	0.59-1.32	.547
	AL- or NHL-type treatment + allo-HSCT		0.17	0.10-0.30	<.001	0.21	0.12-0.39	<.001
	AL- or NHL-type treatment + auto-HSCT		0.20	0.09-0.046	<.001	0.24	0.10-0.59	.002
	Radiotherapy		0.74	0.45-1.22	.242	1.32	0.74-2.35	.353
	Palliative		2.96	2.10-4.16	<.001	2.23	1.48-3.34	<.001
Immunophenotype	CD4⁺ CD56⁺ CD123⁺ TCL1⁺ BDCA2⁺	No	1.90	1.15-3.13	.013
	TdT⁺	No	0.65	0.46-0.93	.019
	CD34⁺ and/or CD117⁺	No	1.19	0.65-2.17	.573
	BCL2⁺	No	2.75	0.55-13.73	.218
Country	Austria	France	0.59	0.37-0.93	.024	0.67	0.42-1.07	.092
	Italy		0.92	0.64-1.34	.676	0.94	0.62-1.42	.752
	Japan		0.58	0.41-0.83	.002	0.66	0.45-0.97	.032
	United States		0.63	0.43-0.92	.018	0.62	0.40-0.97	.035

Variable	Modality	Reference	Univariate analysis			Multivariate analysis
Variable	Modality	Reference	HR	95% CI	P	HR	95% CI	P
Age		Continuous variable	1.05	1.04-1.06	<.001	1.02	1.01-1.03	<.001
ECOG (0-1)	Yes	No	0.23	0.17-0.30	<.001	0.44	0.29-0.66	<.001
Sex	Female	Male	0.86	0.64-1.16	.326
Localization	Disseminated with or without cutaneous localization	Cutaneous isolated	1.57	1.17-2.11	.003	2.31	1.65-3.23	<.001
	Disseminated with cutaneous localization		2.09	1.30-3.35	.002	5.37	3.15-9.	<.001
	Extranodal disease		1.47	0.87-2.51	.154	4.68	2.61-8.40	<.001
Abnormal karyotype	Yes	No	0.78	0.47-1.32	.360
	CK		1.02	0.59-1.77	.938
	MK		0.71	0.33-1.50	.362
Type of treatment	AL-type treatment	NHL-type treatment	0.71	0.51-0.99	.047	0.88	0.59-1.32	.547
	AL- or NHL-type treatment + allo-HSCT		0.17	0.10-0.30	<.001	0.21	0.12-0.39	<.001
	AL- or NHL-type treatment + auto-HSCT		0.20	0.09-0.046	<.001	0.24	0.10-0.59	.002
	Radiotherapy		0.74	0.45-1.22	.242	1.32	0.74-2.35	.353
	Palliative		2.96	2.10-4.16	<.001	2.23	1.48-3.34	<.001
Immunophenotype	CD4⁺ CD56⁺ CD123⁺ TCL1⁺ BDCA2⁺	No	1.90	1.15-3.13	.013
	TdT⁺	No	0.65	0.46-0.93	.019
	CD34⁺ and/or CD117⁺	No	1.19	0.65-2.17	.573
	BCL2⁺	No	2.75	0.55-13.73	.218
Country	Austria	France	0.59	0.37-0.93	.024	0.67	0.42-1.07	.092
	Italy		0.92	0.64-1.34	.676	0.94	0.62-1.42	.752
	Japan		0.58	0.41-0.83	.002	0.66	0.45-0.97	.032
	United States		0.63	0.43-0.92	.018	0.62	0.40-0.97	.035